Overview

Price chart · mood · technical indicators

KNSA

Kiniksa Pharmaceuticals Ltdstock Healthcare

Drug Manufacturers - Specialty & Generic

$57.62113.88%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$24.85$57.72

Current: $57.62

Idea: EMA

1Y Return

+57.5%

Sharpe 3Y

0.93

Market Comparison

vs Healthcare Sector & Drug Manufacturers - Specialty & Generic Industry

KNSA

+113.88%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - Specialty & Generic

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio60.74Forward 50.25

EPS (TTM)$0.91550.0% YoY

Profit margin8.7%HEALTHCARE

Market cap$4.25BMid cap

Wall Street coverage

$63.50median target· current $19.99 (+217.7%)8 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 50.25
PEG ratio: —
P/B: 7.02
P/S (TTM): 6.28
EV/EBITDA: 39.97

Profitability & growth

ROE (TTM): 11.7%
Operating margin: 9.8%
Revenue growth YoY: 65.0%
Dividend yield: —
Beta: 0.06

Last earnings

Mar 3, 2026 · Estimate $0.35 · Reported $0.17

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Kiniksa Pharmaceuticals Ltd

Company profile

Kiniksa Pharmaceuticals Ltd. (KNSA) is a cutting-edge biopharmaceutical company dedicated to addressing high unmet medical needs through the development of innovative therapies. The company's leading candidate, KPL-404, is a targeted monoclonal antibody aimed at modulating B and T lymphocyte activity, potentially transforming treatment options for autoimmune disorders. Kiniksa's robust pipeline, underscored by ongoing clinical trials and strategic collaborations, positions it for significant growth and expansion within the pharmaceutical landscape. With a focus on scientific innovation and a…

Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 105 PICCADILLY, LONDON, UNITED KINGDOM
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$4.25B

Shares outstanding$46.3M

52W high$55.28

52W low$24.85

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

KNSA

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Kiniksa Pharmaceuticals International plc Files 8-K: Announces Consulting Agreement Details and Company Information (April 30, 2026)

Kiniksa (NASDAQ: KNSA) CEO Sanj K. Patel exercises options, sells 48,565 shares under 10b5-1 plan

Kiniksa (NASDAQ: KNSA) CEO’s plan-based option exercises and 508K share sales detailed

KNSA SEC Filings - Kiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms

Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan

Kiniksa (NASDAQ: KNSA) insider sale and cashless exercise flagged in Form 144

KNSA SEC Filings - Kiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms

Kiniksa (KNSA) CAO sells 6,625 shares in Rule 10b5-1 trade

COO share sale: Kiniksa (KNSA) executive sells 1,703 shares under plan

KNSA SEC Filings - Kiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms

Kiniksa (KNSA) Form 144: 6,625 Class A shares tied to restricted stock lapses

Kiniksa Pharmaceuticals (NASDAQ: KNSA) Form 144 shows proposed Class A sales

Kiniksa (KNSA) COO executes RSU exercise and 2,367-share sale under 10b5-1 plan

Kiniksa (NASDAQ: KNSA) CFO exercises 2,694 RSUs, covers tax with shares

Kiniksa (KNSA) CMO exercises 2,497 RSUs; 1,208 shares withheld

Kiniksa (NASDAQ: KNSA) CSO exercises RSUs; 846 shares withheld for tax

Kiniksa (KNSA) CEO Sanj K. Patel exercises options and sells 7,278 shares

Kiniksa (KNSA) CAO nets shares after 3,932 RSUs vest and 1,666 withheld for taxes

Kiniksa (NASDAQ: KNSA) reports 20,000-share cashless exercise sale

219,591-share cashless exercise reported by Kiniksa (NASDAQ: KNSA)

About Kiniksa Pharmaceuticals Ltd

Classification

Company profile

KNSA

Market Comparison

KNSA Market Analysis

Overview

KNSA

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Kiniksa Pharmaceuticals International plc Files 8-K: Announces Consulting Agreement Details and Company Information (April 30, 2026)

Kiniksa (NASDAQ: KNSA) CEO Sanj K. Patel exercises options, sells 48,565 shares under 10b5-1 plan

Kiniksa (NASDAQ: KNSA) CEO’s plan-based option exercises and 508K share sales detailed

KNSA SEC Filings - Kiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms

Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan

Kiniksa (NASDAQ: KNSA) insider sale and cashless exercise flagged in Form 144

KNSA SEC Filings - Kiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms

Kiniksa (KNSA) CAO sells 6,625 shares in Rule 10b5-1 trade

COO share sale: Kiniksa (KNSA) executive sells 1,703 shares under plan

KNSA SEC Filings - Kiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms

Kiniksa (KNSA) Form 144: 6,625 Class A shares tied to restricted stock lapses

Kiniksa Pharmaceuticals (NASDAQ: KNSA) Form 144 shows proposed Class A sales

Kiniksa (KNSA) COO executes RSU exercise and 2,367-share sale under 10b5-1 plan

Kiniksa (NASDAQ: KNSA) CFO exercises 2,694 RSUs, covers tax with shares

Kiniksa (KNSA) CMO exercises 2,497 RSUs; 1,208 shares withheld

Kiniksa (NASDAQ: KNSA) CSO exercises RSUs; 846 shares withheld for tax

Kiniksa (KNSA) CEO Sanj K. Patel exercises options and sells 7,278 shares

Kiniksa (KNSA) CAO nets shares after 3,932 RSUs vest and 1,666 withheld for taxes

Kiniksa (NASDAQ: KNSA) reports 20,000-share cashless exercise sale

219,591-share cashless exercise reported by Kiniksa (NASDAQ: KNSA)

About Kiniksa Pharmaceuticals Ltd

Classification

Company profile

KNSA

Market Comparison